MedinCell Financial Statements From 2010 to 2024
| MDCLF Stock | USD 14.00 7.02 100.57% |
Check MedinCell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MedinCell's main balance sheet or income statement drivers, such as , as well as many indicators such as . MedinCell financial statements analysis is a perfect complement when working with MedinCell Valuation or Volatility modules.
MedinCell |
MedinCell SA Company Operating Margin Analysis
MedinCell's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current MedinCell Operating Margin | (3.25) % |
Most of MedinCell's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MedinCell SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, MedinCell SA has an Operating Margin of -3.2526%. This is 90.73% lower than that of the Healthcare sector and 97.1% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 40.97% lower than that of the firm.
MedinCell SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining MedinCell's current stock value. Our valuation model uses many indicators to compare MedinCell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MedinCell competition to find correlations between indicators driving MedinCell's intrinsic value. More Info.MedinCell SA is considered to be number one stock in return on asset category among its peers. It also is considered to be number one stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the MedinCell's earnings, one of the primary drivers of an investment's value.About MedinCell Financial Statements
MedinCell stakeholders use historical fundamental indicators, such as MedinCell's revenue or net income, to determine how well the company is positioned to perform in the future. Although MedinCell investors may analyze each financial statement separately, they are all interrelated. For example, changes in MedinCell's assets and liabilities are reflected in the revenues and expenses on MedinCell's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MedinCell SA. Please read more on our technical analysis and fundamental analysis pages.
It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. Medincell is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in MedinCell Pink Sheet
MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.